Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

The US Vaccines Market, (excluding COVID-19 vaccines), valued at US$25.98 billion in 2024, is forecasted to grow at a robust ...

First-in-human studies anticipated to begin in 2026Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Financial stocks, including Visa ( V, +2.4%) and Goldman Sachs ( GS, +2.7%), posted solid gains. So did Wells Fargo ( WFC, +2 ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

According to a comprehensive new market analysis titled 'Algal Pigments Market by Type (Beta-Carotene, Astaxanthin, ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...